Omar A. Almohammed - Search Results

Year	Number of Results
2019	2
2020	5
2021	12
2022	18
2023	8
2024	18
2025	24
2026	13

1

Effects of iron and silver nanoparticles on Ctenopharyngodon idella's swimming performance, their bioaccumulation, histological changes, and oxidative stress.

Kakakhel MA, Narwal N, Mahboub H, Elhajji FD, Khan S, Xiaotao S, Dabiellil M, Iqbal MS, Alyami EM, Almohammed OA. Kakakhel MA, et al. Among authors: almohammed oa. Discov Nano. 2026 May 18;21(1):194. doi: 10.1186/s11671-026-04633-3. Discov Nano. 2026. PMID: 42149282 Free PMC article.

2

Niclosamide attenuates skin cancer progression through suppression of key oncogenic pathways: integrated in vivo and in-silico mechanistic insights.

Oraibi AI, Al-Ibadah M, Al-Samydai A, Hussein MN, Al-Hussaniy HA, Saleem M, Almukram A, Tesemma M, Alyami EM, Alghamdi OA, Al-Shammari AH, Elossaily GM, Almohammed OA. Oraibi AI, et al. Among authors: almohammed oa. BMC Cancer. 2026 Apr 17;26(1):698. doi: 10.1186/s12885-026-15999-z. BMC Cancer. 2026. PMID: 41998518 Free PMC article.

3

Exploring the anti-asthmatic effects of HMM: OVA-induced murine model and multi-target in silico analysis.

Shaikh AR, Mobashar A, Sharif A, Akhtar B, Alghamdi OA, Alyami EM, Elossaily GM, Almohammed OA, Metouekel A, Bourhia M. Shaikh AR, et al. Among authors: almohammed oa. Naunyn Schmiedebergs Arch Pharmacol. 2026 Apr 13. doi: 10.1007/s00210-026-05164-5. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 41968215

4

Extract of endophytic fungus Cepalotheca foveolata (N11) inhibits lytic bacteriophage: a study on activity, cytotoxicity, and chemical profiling.

Ullah A, Rehman TU, Khan S, Ali Q, Ali M, Haleem A, Iqbal S, Raashid M, Haq A, Ahmed S, Bogale A, Alqahtani FM, Almohammed OA. Ullah A, et al. Among authors: almohammed oa. Int Microbiol. 2026 Apr;29(4):499-508. doi: 10.1007/s10123-026-00788-2. Epub 2026 Mar 13. Int Microbiol. 2026. PMID: 41820732 Free PMC article.

5

Comorbidities and mortality in colistin-resistant gram-negative infections among hospitalized patients in Qassim, Saudi Arabia.

Almutairi MS, Albulaihed M, Almutairi F, Alsuhaibani Y, Alkathlan M, Alnezary FS, Aljamhan AS, Alresheedi AI, Saleem Z, Almohammed OA. Almutairi MS, et al. Among authors: almohammed oa. Saudi Pharm J. 2026 Feb 27;34(1):9. doi: 10.1007/s44446-026-00069-z. Saudi Pharm J. 2026. PMID: 41758308 Free PMC article.

6

Protective potential of linalool against cyclophosphamide-induced interstitial cystitis: mechanistic insights from experimental and computational approaches.

Anjum I, Arooje A, Saima, Naeem F, Mushtaq MN, Barkat K, Rehman ZU, Hamdani SDA, Jahan S, Dauelbait M, Bouallegue A, Alyami EM, Alyahya HK, Almohammed OA. Anjum I, et al. Among authors: almohammed oa. Naunyn Schmiedebergs Arch Pharmacol. 2026 Feb 26. doi: 10.1007/s00210-026-05126-x. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 41746319

7

Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.

Al-Abdulkarim HA, Alqahtani NS, Al-Shraim M, Almohammed OA. Al-Abdulkarim HA, et al. Among authors: almohammed oa. Front Clin Diabetes Healthc. 2026 Jan 27;6:1677695. doi: 10.3389/fcdhc.2025.1677695. eCollection 2025. Front Clin Diabetes Healthc. 2026. PMID: 41676233 Free PMC article.

8

Patterns of prescription, over-the-counter, and herbal medication use among pregnant women in Buraydah, Saudi Arabia: a cross-sectional study.

Almutairi MS, Saeed MS, Alowias H, Alharbi A, Alnezary FS, Almohammed OA. Almutairi MS, et al. Among authors: almohammed oa. Front Pharmacol. 2026 Jan 2;16:1732619. doi: 10.3389/fphar.2025.1732619. eCollection 2025. Front Pharmacol. 2026. PMID: 41552818 Free PMC article.

9

Creating A Multi-Criteria Decision Analysis Tool to Enhance Value-Based Purchasing of Generic and Biosimilar Medications in Saudi Arabia: A Pilot Study.

Alruthia Y, Alhajri H, Almohammed OA, Balkhi B, Alsaqa'aby MF, Almuqbil MA, Al-Abdulkarim HA, Almutairi AR. Alruthia Y, et al. Among authors: almohammed oa. Clinicoecon Outcomes Res. 2026 Jan 8;18:568722. doi: 10.2147/CEOR.S568722. eCollection 2026. Clinicoecon Outcomes Res. 2026. PMID: 41527573 Free PMC article.

10

Establishing FDA-approved oncology drugs as GPR176 inhibitor through homology modelling, molecular docking, MMGBSA, DFT, and molecular dynamics simulation.

Ishabiyi FO, Umar HI, Dutta T, Onyinye OC, Damola OD, Budagova L, Temesgen D, Bourhia M, Bello RO, Alyami EM, Alsolami M, Almohammed OA. Ishabiyi FO, et al. Among authors: almohammed oa. Sci Rep. 2026 Jan 2;16(1):1859. doi: 10.1038/s41598-025-31607-9. Sci Rep. 2026. PMID: 41484214 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year